About Us
About Us
  • Board Of Directors
  • Collaborators
  • Staff Directory
  • Job Openings
Our Legacy
Our Legacy
  • Achievements
  • History
  • Irene Diamond
  • Photo Gallery
Current Research
Current Research
  • Our Scientists and Labs
    • Paul Bieniasz
    • Cecilia Cheng-Mayer
    • Theodora Hatziioannou
    • David D. Ho
    • Yaoxing Huang
    • Martin Markowitz
    • Moriya Tsuji
  • Core Facilities
    • Personnel
    • Flow Cytometry
    • Microscope Imaging Facility
Clinical Trials
Clinical Trials
  • HIV+
    • Newly Infected With HIV
    • Living With HIV
    • Physicians
    • FAQ's
  • HIV.
    • Healthy Volunteer
    • FAQ's
Focus On HIV
Focus On HIV
  • Facts About HIV and AIDS
  • HIV Biology
    • The HIV Virus Particle
    • The HIV Replication Cycle
Giving Center
Giving Center
  • Online Giving
  • Other Giving Opportunities
  • Financial Summary
News Center
News Center
  • ADARC In The News
  • Seminars
  • Newsletters and Brochures
  • For Journalists
China Aids Initiative
China Aids Initiative
Multimedia Library
Multimedia Library
Talks at ADARC
Talks at ADARC
ADARC Gala
ADARC Gala
  • Gala video
  • Gala photo
  • leadership committee
  • Online Giving
Register for Updates
Register for Updates
Clinical Trails

Living with HIV


If You Are Living With HIV

If you are living with HIV, you may be eligible to participate in one of our clinical trials. Please click the links below if you would like more information about our open trials. If you are interested in participating, please contact Melissa La Mar at 212-327-7280 or e-mail her at mlamar@adarc.org.

Clinical Trials for Patients Living with HIV



(MMA - 0927)
Antiretroviral Therapy as Long Acting Suppression-ATLAS study

A Phase III, randomized, multicenter, parallel-group, noninferiority, open-label study evalua-
ting the efficacy, safety, and tolerability of switching to longacting cabotegravir plus longacting rilpivirine in HIV-1-infected adults who are virologically suppressed.



Antiretroviral Therapy
study by GlaxoSmithKline

A Phase IIb, dose ranging study of oral GSK1265744 in combination with nucleoside reverse transcriptase inhibitors for induction of HIV-1 virologic suppression followed by an evaluation of maintenance of virologic suppression when oral GSK1265744 is combined with oral rilpivirine in HIV-1-infected, antiretroviral therapy naïve adult subjects.